AbbVie is launching Humira on the TrumpRx platform with an 86% discount under a pricing agreement with the White House, a sharp shift for one of the company’s most important drugs. The move is meant to cut out-of-pocket costs and widen access for US patients, while changing how AbbVie prices Humira after exclusivity.
The decision lands while AbbVie shares trade around $206.69, giving investors a fresh reason to weigh the drug’s role in the company’s business. Humira has been central to AbbVie’s position in immunology, and the company has posted a 1-year return of 14.5% and a 5-year return of 131.2%, even as its shares have fallen about 10.2% over the past 30 days.
The discount matters because Humira still represents US$61.2 billion in revenue exposure in the article’s framing, and the pricing move could affect patient volumes, payer relationships and how other high-cost biologics are priced in government-linked programs. AbbVie is trading at a current P/E of about 87.3, carries a high level of debt and offers a 3.35% dividend yield that is not well covered by earnings, adding to the pressure around how much room the company has to absorb pricing changes.
The White House agreement could also shape future pricing discussions beyond Humira. The article says it may influence competitor responses in US biologics and raise the question of whether similar frameworks will be extended to other AbbVie products, even though no such plans are confirmed.
Simply Wall St said it had flagged five risks for AbbVie, including a share price that sits about US$249.14 versus the current level around $206.69 and about 43.8% below an estimated fair value. For investors, the key issue is no longer whether AbbVie can protect Humira’s franchise, but how far this TrumpRx deal reaches into the rest of its US business.
